confirm win rcc forecast chang
gu data keytruda upsid rcc
base keytruda inlyta data present gu
increas po increas keytruda rcc revenu
believ drive margin expans takeaway detail present
nejm publication/editori includ strong benefit across subgroup editori
mention uncondit new standard care rcc updat
pdufa june increas keytruda rcc sale out-year
modest upsid potenti depend competitor attrit reit buy rate
data exce expect os
follow abstract releas monday highlight increment takeaway mrk
os benefit p/i group hr doesnt come surpris given
strength all-com data hr respons rate data reveal cr rate
 vs sutent lower cr nejm author note
could still evolv given median fu shape os curv demonstr
critic plateau drive belief onc impli durabl nejm editori commentari
note combo becom new standard care unlik javelin renal
keytruda regimen conting upon demonstr surviv benefit
forecast reflect peak out-year rcc keytruda sale assum
captur share major market assum major share captur come
bmi p/i patient tki mono favorable-risk patient view rcc
global market sale come us new incid
population/year main risk rcc estim bmi show
superior efficaci believ unlik base high bar set
keytruda drive favor margin estim
forecast keytruda sale con level
also forecast oper margin bp prior forecast
time-frame estim competitor attrit lung indic could add
increment sale translat bp increment margin
expans depend outcom bmi part studi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
asco gu american societi clinic
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharma compani focus
discov develop market drug
infecti diseas oncolog
indic compani global leader
vaccin diversifi anim
rate buy offer attract valuat
good track record return cash
sharehold diversifi revenu base
substanti pipelin potenti keytruda
exhibit detail data gu
follow month
durat respons month
discont due trae
follow
previous report data grade p-valu report
gu compani present abstract motzer et al nejm
price object po base blend averag risk-adjust
discount cash flow dcf price-to-earnings multipl appli ep dcf assum
wacc termin growth rate believ dcf assumpt
reason given minim contribut new keytruda indic
yet valid late-stag clinic studi erod revenu base
januvia/janumet zepati neg termin growth target price-to-earnings
multipl base regress analysi histor us major pharma
forward price-to-earnings multipl three-year forward compound-annual-growth-rate non-gaap
risk competitor report result look substanti better
shown keytruda chemotherapi higher-than-anticip price pressur
diabet franchis neg result late-stag clinic program
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
